Sanofi US

An R&D driven, AI-powered biopharma company committed to improving lives. For U.S. residents only. Interactions must comply with terms:

[Sanofi US @SanofiUS]

Every day, we chase the miracles of science so you can chase your dreams.

Learn more about how we’re chasing the miracles of science: https://t.co/PTATayJ9CX

[Sanofi US @SanofiUS]

Our new drug application for our first-in-class investigational oral molecule for type 3 Gaucher disease (GD3) has been accepted for priority review by the @US_FDA. Learn more: https://t.co/mRz9sHsIgm

[Sanofi US @SanofiUS]

Today at #ATS we presented for the first time, data that our investigational treatment for #AATD met all primary and key secondary endpoints. These findings reinforce our commitment to innovation for people living with this rare disease ⬇️

https://t.co/VyHzKYJqEN

[Sanofi US @SanofiUS]

At Digestive Disease Week, we’re sharing late-breaking results from our phase 4 study in adults with eosinophilic esophagitis (EoE), a progressive disease that can cause narrowing of the esophagus.

Learn more here: https://t.co/0yE97NFjGD

@Regeneron

[Sanofi @sanofi]

Our Q1 2026 results are now available.
See the press release for more details: https://t.co/McL3v5nR1p

#SanofiResults $SAN $SNY

[Sanofi US @SanofiUS]

The @US_FDA has approved our medicine for certain children aged 2-11 years with uncontrolled chronic spontaneous urticaria (CSU), a chronic skin disease. Read more: https://t.co/dSEJY1nShN

[Sanofi US @SanofiUS]

The @US_FDA has approved a treatment for eligible young children with #Type1Diabetes. With this approval, we hope to better support these young T1D patients and their families. Learn more ⬇️

https://t.co/m5ePptkx1K

[Sanofi US @SanofiUS]

#NEWS: COMPARE study presented at #ESCMIDGlobal2026: head-to-head tolerability comparison of a protein-based and an mRNA COVID-19 vaccine.

Learn more ⬇️

https://t.co/en3b7Dtqt4

[Sanofi US @SanofiUS]

@US_FDA grants Breakthrough Therapy Designation to our investigational product for Gaucher disease type 3. Learn more: https://t.co/5K1aOQRqVO

[Sanofi US @SanofiUS]

Proud to announce Sanofi is an Official Supporter of @FIFAWorldCup Boston 2026! With ~5K employees & our largest US site in MA, we're all in for Commonwealth. Science meets community on the world's biggest stage! 🌍 Learn more: https://t.co/Sxowjc9OJF

[Sanofi US @SanofiUS]

The @US_FDA has approved our medicine as the first and only medicine for allergic fungal rhinosinusitis (AFRS) in certain adults and children aged 6 years and older. Learn more: https://t.co/pBFw9XNO8E

CC: @Regeneron

[Sanofi US @SanofiUS]

@US_FDA @MHLWitter_en Read more ⬇️
https://t.co/Ki3Q2vJB0c

[Sanofi US @SanofiUS]

Our investigational BTK inhibitor for the potential treatment of wAIHA was granted Breakthrough Therapy Designation by @US_FDA and Orphan Drug by @MHLWitter_en in Japan, highlighting our commitment to advancing therapies for #RareDiseases with significant unmet need.

[Sanofi US @SanofiUS]

Phase 3 study results of our investigational oral therapy for Fabry disease and type 3 Gaucher disease are now available.

Discover more about our ongoing #RareDisease research. ⬇️

https://t.co/RlKXNuvht8

[Sanofi @sanofi]

Our Q4 and full-year 2025 results are now available.

Learn more: https://t.co/5Yd1f7gXCC

#SanofiResults $SAN $SNY

[Sanofi US @SanofiUS]

The @US_FDA accepted for Priority Review our sBLA for children between one and eight years of age with stage 2 #Type1Diabetes. Learn more about this milestone ⬇️

https://t.co/0j4tC7qBE2

[Sanofi US @SanofiUS]

On #VeteransDay, we salute all who served — including Lois and Adam from our VETS Employee Business Resource Group (EBRG).

Their leadership continues to drive impact for patients and communities every day.

Thank you to all veterans for your courage and dedication.

[Sanofi US @SanofiUS]

New phase 3 results from our investigational medicine for allergic fungal rhinosinusitis (AFRS) in adults and children over age 6 will be presented at #ACAAI25 and have been accepted for priority review by the US FDA. Learn more.

CC: @RegeneroNew phase 3 results from our investigational medicine for allergic fungal rhinosinusitis (AFRS) in adults and children over age 6 will be presented at #ACAAI25 and have been accepted for priority review by the US FDA. Learn more.

CC: @Regeneron

[Sanofi US @SanofiUS]

We’re presenting new data at #ASH25 showcasing important progress towards our goal of pioneering scientific innovation to evolve care for patients living with rare diseases and blood cancers.

Read more about our research ⬇We’re presenting new data at #ASH25 showcasing important progress towards our goal of pioneering scientific innovation to evolve care for patients living with rare diseases and blood cancers.

Read more about our research ⬇We’re presenting new data at #ASH25 showcasing important progress towards our goal of pioneering scientific innovation to evolve care for patients living with rare diseases and blood cancers.

Read more about our research ⬇️

[Sanofi US @SanofiUS]

Sanofi and our partner Regeneron were honored this week to accept the #PrixGalien “Best Biotechnology Product” award from @GalienFdn. Thank you to the people and partners who make our work possible.

Learn more about this recognition ⬇️

#biotechnology